Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis

Table 3 Analyses of secondary outcomes in urologic cancers

Secondary outcomes	No. of studies	No. of cases	Pooled HR (95% CI)	P-value	Heterogeneity
Secondary outcomes	No. of studies	No. of cases	Pooled HR (95% CI)	P-value	I²	Model
PFS	7	1554	1.92 (1.29, 2.88)	0.001	93	Random
CSS	2	600	2.58 (1.36, 4.91)	0.004	7	Random
ORR	2	448	0.40 (0.22, 0.71)	0.002	0	Fixed
DCR	2	448	0.93 (0.11, 8.05)	0.950	95	Random

CI: confidence interval; CSS: cancer‐specific survival; DSS: disease‐specific survival; ORR: overall response rate; DCR: disease control rate; HR: hazard ratio; SII: systemic immune‐inflammation index

ISSN: 1475-2867